Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2022

View Archived Issues

P-selectin associated with COVID-19 severity and mortality

BMP-9 is required for survival after acute myocardial infarction

VBI Vaccines reports new preclinical data from coronavirus program VBI-2900

Targinta selects TARG-9 as drug candidate

Discovery may allow more selective chemokine targeting

NUAK1 inhibition as new antifibrotic treatment strategy

Elevated troponin in patients with COVID-19 is an independent risk factor for mortality

OPG is an independent factor for coronary artery calcification in hypertension

Shaanxi Micot Technology discloses new CaSR agonists

New HBV antiviral compounds patented by Janssen

Gasherbrum Bio presents new GLP-1 receptor agonists

Schroedinger identifies new CDC7 inhibitors

New SPNS2 inhibitors synthesized by University of Virginia

PEAR1 genetic variation tied to big endothelin levels in patients with acute myocardial infarction

Atreca announces agreement with Zymeworks and selection of new clinical candidate

Can-Fite developing topical formulation of piclidenoson for the treatment of psoriasis

NOX2 inhibition reverses obesity-induced atrial fibrillation

N-LIfT results in complete cell killing in solid tumor organoids

ACE2-independent blood cell infection linked to severe COVID

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...